CollPlant Biotechnologies Aktie

REHOVOT, Israel, April 25, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that CEO Yehiel Tal will moderate the International Society for Biofabrication's (ISBF) virtual event on May 2nd. Mr. Tal also serves as a board member of ISBF. ISBF’s virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening ISBF’s virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening The event will be hosted by the ISBF's Industry Relations Committee and feature experts in the field from academia and industry: Dr. Daniel Levner, co-founder and CTO of Emulate, Dr. Ben Maoz from Tel Aviv University, Dr. Lutz Kloke, founder and CSO of Cellbricks and Dr. Jeroen Eyckmans from Boston University. The Q&A session will be moderated by Ms. Katie Weimer, VP Regenerative Medicine at 3D systems and a member of the ISBF's Industry Relations Committee. Event title: Biofabrication of Microphysiological Systems for Drug Discovery and Screening - Future Outlook Date: Monday, May 2, 2022 Time: 10:00 AM EST / 4:00 PM CET / 11:00 PM JST Location: Virtual event Registration link The Industry Relations Committee of ISBF is serving as a mediator of academia-industry and industry-industry to promote and stimulate collaboration; developing mechanisms to facilitate translation of laboratory discoveries into manufactured products; and representing the industry in all Biofabrication aspects including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization. For more details and to register, please visit https://biofabricationsociety.org/ About the International Society for Biofabrication From basic science to medical applications, the biofabrication community convened at the International Conference on Biofabrication (Biofabrication 2019). The field of biofabrication is dedicated to researching and integrating technologies such as bio-printing, bio-plotting, and bio-assembly into applications such as engineered tissue systems and regenerative medicine. The International Society for Biofabrication's (ISBF) core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity. ISBF promotes the interaction between and convergence in the different disciplines of the field of Biofabrication, as well as between basic research and applied practice. Further, the Society aims to promote the cooperation with other scientific organizations and communities. About CollPlant CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. At the beginning of 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

find ich sagenhaft,diese technologie aus israel,die konnten damit schon 15 mio umsatz und einen kleinen gewinn machen,aber was wird da in zukunft erst moeglich werden ??? collPlant Biotechnologies Ltd. (CLGN) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Add to watchlist Quote Lookup 9.01-0.28 (-3.01%)